Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL

NCT06051409 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT06051409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06051409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2023
Completion date
June 30, 2029
Enrollment
350 (estimated)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoblastic, acute, philadelphia-positive, ph+ all